37 terminated. 37 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 37 | Terminated 37 |
| Phase 2 | 2 | Terminated 2 |
Follow Anemia, Hemolytic: new trials by email Literature Review of Anemia, Hemolytic trials Research Report on Anemia, Hemolytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD) Osivelotor - Sickle Cell Disease | Phase 2 / Phase 3 | Terminated | Pfizer | 47 | 2023-01-05 | 2026-03-19 |
| Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Cemdisiran, Eculizumab, Pozelimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 3 | 2022-10-06 | 2025-04-08 |
| Voxelotor Neurocognitive Function Study Voxelotor Only Product in Oral Dose Form, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 1 | 2022-06-24 | 2024-05-02 |
| THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) Rivaroxaban 10 MG, Placebo - Sickle Cell Disease, Central Venous Catheter Thrombosis | Phase 3 | Terminated | University Health Network, Toronto | 4 | 2022-06-07 | 2025-03-19 |
| Resolution of Sickle Cell Leg Ulcers With Voxelotor Voxelotor Oral Tablet, Placebo - Sickle Cell Disease, Leg Ulcers | Phase 3 | Terminated | Pfizer | 88 | 2022-05-30 | 2025-07-09 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults. Sufentanil, EMONO - Sickle Cell Crisis | Phase 3 | Terminated | University Hospital, Bordeaux | 115 | 2021-07-20 | 2026-06-22 |
| Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease Voxelotor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 236 | 2020-11-11 | 2026-03-10 |
| Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome | Phase 3 | Terminated | Dr. med. Mahir Karakas | 68 | 2020-02-21 | 2022-05-24 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability. REGN3918 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | Regeneron Pharmaceuticals | 24 | 2019-12-03 | 2023-06-12 |
| Open-Label Extension of Voxelotor Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 162 | 2019-11-18 | 2025-11-13 |
| Comparing Individualized vs. Weight Based Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease Patient-Specific Protocol, Weight-based Protocol, Morphine - Sickle Cell Disease | Phase 3 | Terminated | Duke University | 328 | 2019-08-13 | 2023-07-03 |
| Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS INM004, Placebo - Bloody Diarrhea, STEC, Unspecified | Phase 2 / Phase 3 | Terminated | Inmunova S.A. | 11 | 2019-07-17 | 2023-07-19 |
| Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Ticagrelor, Placebo - Sickle Cell Disease | Phase 3 | Terminated | AstraZeneca | 193 | 2018-09-26 | 2021-04-09 |
| Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 Voxelotor - Sickle Cell Disease | Phase 3 | Terminated | Pfizer | 179 | 2018-06-06 | 2025-11-18 |
| Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis Denosumab 60 MG/ML Prefilled Syringe, Zoledronic Acid 5Mg/Bag 100Ml Inj - Thalassemia Majors (Beta-Thalassemia Major), Osteoporosis | Phase 3 | Terminated | Hamad Medical Corporation | 17 | 2018-05-14 | 2019-12-12 |
| Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome OMS721 (narsoplimab) - Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome | Phase 3 | Terminated | Omeros Corporation | 6 | 2018-05-02 | 2025-12-10 |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study rVA576 - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Terminated | AKARI Therapeutics | 15 | 2017-03-13 | 2025-04-10 |
Showing 20 of 37. Sign in to see all of them.
Anemia, Sickle Cell (28) · Vaso-Occlusive Crises (8) · Hematologic Diseases (3) · Hemoglobinuria, Paroxysmal (3) · Hypertension, Pulmonary (3) · Acute Chest Syndrome (2) · Agnosia (2) · Hemolytic-Uremic Syndrome (2) · Atypical Hemolytic Uremic Syndrome (1) · Bacterial Infections (1) · Communicable Diseases (1) · Escherichia coli Infections (1) · Hemochromatosis (1) · Immune System Diseases (1) · Iron Overload (1)
Anemia (37) · Hemic and Lymphatic Diseases (37) · Hematologic Diseases (34) · Anemia, Hemolytic, Congenital (31) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31) · Genetic Diseases, Inborn (31) · Hemoglobinopathies (31) · Cardiovascular Diseases (5) · Lung Diseases (5) · Respiratory Tract Diseases (5) · Vascular Diseases (5) · Nervous System Diseases (4) · Blood Platelet Disorders (3) · Bone Marrow Diseases (3)
voxelotor (4) · Bosentan (3) · Hydroxyurea (3) · Erythrocyte Transfusion (2) · inclacumab (2) · senicapoc (2) · Aspirin (1) · Atorvastatin (1) · Deferasirox (1) · Denosumab (1) · Dexamethasone (1) · Dosage Forms (1) · Exercise (1) · Hydromorphone (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)
Pfizer (8) · Actelion (3) · Children's Hospital Medical Center, Cincinnati (3) · Icagen (2) · Regeneron Pharmaceuticals (2) · AKARI Therapeutics (1) · Abigail Nixon (1) · AstraZeneca (1) · Baylor College of Medicine (1) · Carelon Research (1) · Children's Hospital Los Angeles (1) · Dr. med. Mahir Karakas (1) · Duke University (1) · Eli Lilly and Company (1) · GlycoMimetics Incorporated (1)
United States (24) · United Kingdom (9) · Brazil (7) · Kenya (7) · Lebanon (6) · Nigeria (6) · Canada (5) · Egypt (5) · Italy (5) · Oman (5) · Turkey (Türkiye) (5) · France (4) · Saudi Arabia (4) · Ghana (3) · Belgium (2)
Russell E. Ware, MD, PhD (3) · Anders Berggren, MD, PhD (1) · Carlton Dampier, MD (1) · Charles Quinn, MD (1) · Howard Trachtman (1) · Huiman Barnhart, PhD (1) · Irina M Kline, MD (1) · Jonathan W Stocker, Ph.D. (1) · Jonathan W Stocker, PhD (1) · Lorna M Williamson, MRCP,MRCPath (1) · Mahir Karakas, MD (1)
PMID 20175775, PMID 34219224, PMID 40277027, PMID 12966125, PMID 21826782, PMID 21848879, PMID 22318199, PMID 23539110, PMID 23861242, PMID 24914136, PMID 26414435, PMID 26644172, PMID 26670617, PMID 31446143, PMID 33783815, PMID 35849650, PMID 35981565, PMID 38171625, PMID 39154808, PMID 41249873, PMID 42665434
2019 (4), 2017 (1), R01DK052147 (1), R01HL095647 (1), R01HL098239 (1), U01HL078787 (1), U10HL083721 (1), U24HL137907 (1), U54HL070587 (1)